Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

NCT05429684 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

HER2+ Breast Cancer

Interventions

DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Nab paclitaxel
DRUG: Pyrotinib
DRUG: Capecitabine
DRUG: T-DM1
DRUG: Everolimus
DRUG: CDK4/6 inhibitor
DRUG: AI
DRUG: Anti-PD-1 monoclonal antibody

Sponsor

First Affiliated Hospital Xi'an Jiaotong University